MDXH
MDxHealth SA ADRNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$103.76M
P/E Ratio
—
EPS
$-0.67
Beta
-537543.56
52W High
$5.33
52W Low
$1.40
50-Day MA
$3.28
200-Day MA
$3.40
Dividend Yield
—
Profit Margin
-31.10%
Forward P/E
27.70
PEG Ratio
—
About MDxHealth SA ADR
MDxHealth SA is a pioneering biotechnology company focused on precision diagnostics that enhance cancer management, particularly for prostate and bladder cancers. The company has developed and commercialized advanced diagnostic solutions, including its flagship product, ConfirmMDx for Prostate Cancer, which is recognized for its clinical efficacy and strong market presence. As the field of personalized medicine advances and the need for targeted cancer therapies rises, MDxHealth is well-positioned to expand its innovative offerings and address significant unmet needs in oncology, ultimately aiming to improve patient outcomes and drive growth.
Fundamentals
| Revenue (TTM) | $107.88M |
| Gross Profit (TTM) | $69.63M |
| EBITDA | $-5.20M |
| Operating Margin | -17.80% |
| Return on Equity | -2440.00% |
| Return on Assets | -5.90% |
| Revenue/Share (TTM) | $2.16 |
| Book Value | $-0.23 |
| Price-to-Book | 23.64 |
| Price-to-Sales (TTM) | 0.96 |
| EV/Revenue | 1.562 |
| EV/EBITDA | 17.57 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 19.40% |
| Shares Outstanding | $51.37M |
| Float | $36.02M |
| % Insiders | 11.18% |
| % Institutions | 49.59% |
Analyst Ratings
Consensus ($7.40 target)
6
BuyData last updated: 4/8/2026